Indoco Remedies has informed that, as informed in its quarterly MDA Synpsis, the Company was expecting re-inspection of Goa Plant I and Plant II by USFDA. Inspection of Goa PIant II (Sterile facility) was completed from 14 - 21 November, 2018 and Goa Plant I (Solid oral facility) inspection by USFDA has commenced since 17th January, 2019.
The above information is a part of company’s filings submitted to BSE.